194 related articles for article (PubMed ID: 7814637)
1. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics.
Beckers CJ; Roos DS; Donald RG; Luft BJ; Schwab JC; Cao Y; Joiner KA
J Clin Invest; 1995 Jan; 95(1):367-76. PubMed ID: 7814637
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin.
Pfefferkorn ER; Borotz SE
Antimicrob Agents Chemother; 1994 Jan; 38(1):31-7. PubMed ID: 8141576
[TBL] [Abstract][Full Text] [Related]
3. A plastid organelle as a drug target in apicomplexan parasites.
Fichera ME; Roos DS
Nature; 1997 Nov; 390(6658):407-9. PubMed ID: 9389481
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Toxoplasma gondii protein synthesis by azithromycin.
Blais J; Garneau V; Chamberland S
Antimicrob Agents Chemother; 1993 Aug; 37(8):1701-3. PubMed ID: 8215287
[TBL] [Abstract][Full Text] [Related]
5. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii.
Camps M; Arrizabalaga G; Boothroyd J
Mol Microbiol; 2002 Mar; 43(5):1309-18. PubMed ID: 11918815
[TBL] [Abstract][Full Text] [Related]
6. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.
Blais J; Tardif C; Chamberland S
Antimicrob Agents Chemother; 1993 Dec; 37(12):2571-7. PubMed ID: 7509143
[TBL] [Abstract][Full Text] [Related]
7. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii.
Fichera ME; Bhopale MK; Roos DS
Antimicrob Agents Chemother; 1995 Jul; 39(7):1530-7. PubMed ID: 7492099
[TBL] [Abstract][Full Text] [Related]
8. Toxoplasma gondii: a simple Real-time PCR assay to quantify the proliferation of the apicoplast.
Wu L; Chen SX; Jiang XG; Cao JP
Exp Parasitol; 2009 Dec; 123(4):384-7. PubMed ID: 19720060
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
Ramya TN; Mishra S; Karmodiya K; Surolia N; Surolia A
Antimicrob Agents Chemother; 2007 Jan; 51(1):307-16. PubMed ID: 17060533
[TBL] [Abstract][Full Text] [Related]
10. Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin.
Pereyre S; Renaudin H; Charron A; Bébéar C; Bébéar CM
J Antimicrob Chemother; 2006 Apr; 57(4):753-6. PubMed ID: 16464889
[TBL] [Abstract][Full Text] [Related]
11. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA.
Garza-Ramos G; Xiong L; Zhong P; Mankin A
J Bacteriol; 2001 Dec; 183(23):6898-907. PubMed ID: 11698379
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.
Chamberland S; Kirst HA; Current WL
Antimicrob Agents Chemother; 1991 May; 35(5):903-9. PubMed ID: 1854172
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by Toxoplasma gondii but are able to control infection.
Franco PS; Gomes AO; Barbosa BF; Angeloni MB; Silva NM; Teixeira-Carvalho A; Martins-Filho OA; Silva DA; Mineo JR; Ferro EA
Placenta; 2011 Nov; 32(11):838-44. PubMed ID: 21908042
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept study.
Ni Nyoman AD; Lüder CG
Apoptosis; 2013 Jun; 18(6):664-80. PubMed ID: 23468121
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of drug effects on Toxoplasma gondii nuclear and plastid DNA replication using real-time PCR.
Zhao Q; Zhang M; Hong L; Zhou K; Lin Y
Parasitol Res; 2010 Apr; 106(5):1257-62. PubMed ID: 20186551
[TBL] [Abstract][Full Text] [Related]
16. [New pathogens and mode of action of azithromycin: Toxoplasma gondii].
Derouin F
Pathol Biol (Paris); 1995 Jun; 43(6):561-4. PubMed ID: 8539083
[TBL] [Abstract][Full Text] [Related]
17. [In vitro measurement of the inhibitory effect of macrolides, lincosamides and synergestines on the growth of Toxoplasma gondii].
Derouin F; Nalpas J; Chastang C
Pathol Biol (Paris); 1988 Dec; 36(10):1204-10. PubMed ID: 3070460
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities.
Poulsen RL; Knudsen JD; Petersen MB; Fuursted K; Espersen F; Frimodt-Møller N
APMIS; 1996 Mar; 104(3):227-33. PubMed ID: 8611198
[TBL] [Abstract][Full Text] [Related]
19. In-vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant Plasmodium falciparum.
Biswas S
J Postgrad Med; 2001; 47(4):240-3. PubMed ID: 11832638
[TBL] [Abstract][Full Text] [Related]
20. Ribosomal protein P2 localizes to the parasite zoite-surface and is a target for invasion inhibitory antibodies in Toxoplasma gondii and Plasmodium falciparum.
Sudarsan R; Chopra RK; Khan MA; Sharma S
Parasitol Int; 2015 Feb; 64(1):43-9. PubMed ID: 25280460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
